Enabling better pharmaceuticals

PolyTherics provides an extensive suite of technologies to enable the development of better biopharmaceutical products.

Technology toolbox

Our range of technologies for the site specific conjugation of cytotoxic drugs to create more homogeneous and stable antibody drug conjugates (ADCs) and our reagents and polymers for optimising the pharmacokinetics and pharmacodynamics of proteins, peptides and antibodies enable you to modify your therapeutic product to produce the desired clinical benefit. In addition, we provide complementary immunogenicity testing, antibody humanisation, protein engineering and manufacturing cell line development technologies through Antitope, our wholly owned subsidiary, to improve the safety and reduce the risk of loss of efficacy of biopharmaceutical candidates before they enter the clinic.
Find out more

Collaboration options

We offer product-specific licences for the application of our conjugation, antibody humanisation and protein engineering technologies to enable the development of better biopharmaceuticals. We provide, through Antitope, a comprehensive service for the preclinical prediction of clinical immunogenicity, and for the generation of humanised antibodies, therapeutic proteins, manufacturing cell lines and recombinant vaccines.
Find out more

Antibody drug conjugates

Our site-specific conjugation technologies have the flexibility to link your therapeutic or diagnostic payload (e.g. cytotoxic drug, toxin or radionuclide) to virtually any protein, peptide or antibody that binds to a specific target to create a protein or antibody drug conjugate (ADC).

C:akepath'42_Diagram_AntibodyDC_Roundel.pngFind out more

 

Immunogenicity testing and antibody humanisation

Our immunogenicity testing, antibody humanisation and protein engineering technologies will reduce the immunogenic potential of your products before they enter the clinic and thus improve their safety and reduce the risk of loss of efficacy.

C:akepath'42_Diagram_AntibodyDC_Roundel.pngFind out more

 

New product formats

Our site-specific conjugation technologies can be used to rapidly produce a range of novel product candidates by linking two versions of the same protein or proteins with different binding entities together, including antibody fragments, alternative scaffolds, and peptides.

C:akepath'42_Nature_Bio_roundel.png

Find out more

PK/PD Optimisation

The conjugation of poly(ethylene glycol) (PEG) to a therapeutically active molecule can extend its half-life and thus its duration of action. We have a range of technologies for the site-specific conjugation of PEG (PEGylation), or other polymers, to proteins and peptides.

C:akepath'42_Central_Graph_roundel.pngFind out more

 

Targeted delivery

PolyTherics’ novel glycopolymer (GlycoPol™) is available for the delivery of a pharmacologically active agent to cells that differentially express a binding protein or sugar receptor that can be targeted with a specific mono-, di- or polysaccharide.

C:akepath'42_Cell_Image_roundel.png

Find out more